What is the appropriate treatment for bronchiectasis?

Treatment of Bronchiectasis

Airway clearance techniques and long-term antibiotics for patients with frequent exacerbations form the foundation of bronchiectasis management, with treatment escalation based on exacerbation frequency and microbiology. 1

Initial Assessment and Etiological Testing

Before initiating treatment, perform a minimum bundle of diagnostic tests 1:

• Differential blood count
• Serum immunoglobulins (IgG, IgA, IgM)
• Testing for allergic bronchopulmonary aspergillosis (ABPA)
• Sputum culture for bacterial pathogens (routine monitoring)
• Consider mycobacterial culture if non-tuberculous mycobacteria suspected 1

Additional investigations should target specific aetiologies including cystic fibrosis, GORD, CVID, and inflammatory bowel disease in severe or rapidly progressive cases 1.

Core Treatment Components

Airway Clearance (All Patients)

Teach patients an airway clearance technique to perform once or twice daily, delivered by a trained respiratory physiotherapist 1. This remains the cornerstone of management regardless of disease severity 2.

Vaccination (All Patients)

• Annual influenza vaccination 1
• Polysaccharide pneumococcal vaccination (23-valent) 1
• Consider 13-valent protein conjugate pneumococcal vaccine if inadequate serological response to standard vaccine 1

Pulmonary Rehabilitation

Strongly recommend pulmonary rehabilitation for patients with impaired exercise capacity or dyspnea 1, 3. All patients should engage in regular exercise tailored to their physical capability 1.

Treatment Algorithm Based on Exacerbation Frequency

Step 1: Fewer than 3 Exacerbations per Year

• Airway clearance techniques 1
• Treat acute exacerbations with 14 days of antibiotics (may adjust based on severity and response) 1
• Physiotherapy optimization 1

Step 2: 3 or More Exacerbations per Year Despite Step 1

Consider long-term antibiotic prophylaxis 1:

For Chronic Pseudomonas aeruginosa Infection:

• First-line: Inhaled colistin 1
• Second-line: Inhaled gentamicin (if colistin not tolerated) 1
• Alternative: Macrolides (azithromycin or erythromycin) if inhaled antibiotics contraindicated, not tolerated, or not feasible 1
• Consider adding macrolide to inhaled antibiotic if high exacerbation frequency persists 1

For Non-Pseudomonas Pathogens or No Pathogen:

• First-line: Long-term macrolides (azithromycin or erythromycin) 1
• Alternative: Oral antibiotic based on susceptibility if macrolides contraindicated or ineffective 1
• Consider inhaled antibiotics if oral prophylaxis fails 1

Critical safety measures before starting long-term antibiotics 1:

• For macrolides: Ensure at least one negative NTM culture; use caution with significant hearing loss or balance issues
• For inhaled aminoglycosides: Avoid if creatinine clearance <30 mL/min; use caution with hearing loss; avoid concomitant nephrotoxic medications

Step 3: Persistent High Exacerbation Frequency

• Reassess physiotherapy and add mucoactive treatment if difficulty expectorating sputum 1
• Combine macrolide with inhaled antibiotic for P. aeruginosa patients 1

Step 4: 5 or More Exacerbations per Year Despite Step 3

Consider regular intravenous antibiotics every 2-3 months 1

Specific Clinical Scenarios

New Isolation of Pseudomonas aeruginosa

Offer eradication therapy 1:

• First-line: Ciprofloxacin 500-750 mg twice daily for 2 weeks 1
• Second-line: IV antipseudomonal beta-lactam ± IV aminoglycoside for 2 weeks, followed by 3 months of nebulized colistin, gentamicin, or tobramycin 1
• Send sputum for culture immediately before and after treatment to confirm eradication 1

New Isolation of MRSA

Offer eradication therapy, particularly for infection control 1

Mucoactive Agents

Consider long-term mucoactive treatment (≥3 months) in patients with difficulty expectorating sputum and poor quality of life where standard airway clearance fails 1.

Do NOT use recombinant human DNase - this is strongly contraindicated 1.

What NOT to Routinely Use

• Do not routinely prescribe inhaled corticosteroids for bronchiectasis alone 1 (use only if comorbid asthma or COPD exists) 1
• Do not offer statins for bronchiectasis treatment 1
• Do not routinely offer long-acting bronchodilators unless significant breathlessness present 1 (use if comorbid asthma or COPD) 1

Advanced Disease Management

Surgical Resection

Consider lung resection only for localized disease with uncontrolled symptoms despite optimized medical management 1. Requires multidisciplinary assessment including bronchiectasis physician, thoracic surgeon, and experienced anesthetist 1.

Transplant Referral

Consider transplant referral in patients ≤65 years if 1:

• FEV₁ <30% with significant clinical instability, OR
• Rapid progressive respiratory deterioration despite optimal management, OR
• Massive hemoptysis, severe pulmonary hypertension, ICU admissions, or respiratory failure requiring NIV

Oxygen and Ventilatory Support

• Long-term oxygen therapy using same criteria as COPD 1
• Domiciliary non-invasive ventilation with humidification for hypercapnic respiratory failure with symptoms or recurrent hospitalization 1

Common Pitfalls to Avoid

The evidence shows inhaled antibiotics reduce exacerbations and improve quality of life 4, but antibiotic-resistant organisms likely increase with treatment 4. Therefore, antimicrobial stewardship is critical 1. Perform challenge testing before starting inhaled antibiotics to assess tolerability 1. Use bronchodilators before physiotherapy and inhaled antibiotics to optimize deposition 1.